prostate health

Tissue-based PCa assays not robust to multifocalityTissue-based prognostic biomarker assays for prostate cancer are not robust to tumor multifocality and heterogeneity, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
Data cast light on ED/5-ARI connection
Side effects of modern PCa treatments comparedDespite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study.
Hypothermia during RARP: No significant benefit seenAlthough theory and preliminary clinical data indicated that intraoperative regional hypothermia could improve the return to potency and continence after robot-assisted radical prostatectomy, the intervention did not have any significant benefits when put to the more rigorous test of a randomized controlled trial.
Urethral lift: 5-year data point to procedure’s durabilityAnalyses of data from 5 years of prospective follow-up in the pivotal trial supporting regulatory approval of the prostatic urethral lift ([PUL] UroLift System, NeoTract) show that the minimally invasive procedure remains safe and provides rapid and durable benefits for men with symptomatic BPH.
Is focal therapy the future of treatment for localized PCa?"For low-grade disease, it’s certainly worth a try because nothing is really lost. For high-grade disease, I don’t know that it’s appropriate—we don’t have the data," says one urologist.
18F-choline PET/CT detects PCa recurrences early Three out of four patients with prostate cancer with an 18F-choline positron emission tomography/computed tomography–detected recurrence were potentially salvageable with local therapy or metastasis-directed therapy (MDT), according to results of the screening phase of the phase II STOMP randomized trial.